Kinki University
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
1
Ending by 2030
Jan 2030
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 24, 2027The maintenance fee for Composition for ameliorating peripheral sensory neuropathy (US 11,793,845) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
- 1 fee due Jun 8, 2027The maintenance fee for Hard tissue regeneration material and hard tissue regeneration method (US 9,205,030) comes due Jun 8, 2027. Unpaid by Dec 8, 2027, it lapses early.
- 2 fees due Jul 16 to 23, 2027 · next Jul 16
- 1 fee due Aug 18, 2027The maintenance fee for Method for Producing Carbon Nanotube Sheet and Carbon Nanotube Sheet (US 10,562,775) comes due Aug 18, 2027. Unpaid by Feb 18, 2028, it lapses early.
- 2 fees due Oct 9 to 28, 2027 · next Oct 9
Recent changes
- 2 of the patents on this record were granted since Aug 16, 2026
- 3 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,383,595 | Peptide derivative and composition for promoting tear secretion comprising the same In force · From the USPTO record | In force | From the USPTO record | |
| US 9,205,030 | Hard tissue regeneration material and hard tissue regeneration method In force · From the USPTO record | In force | From the USPTO record | |
| US 8,897,862 | Fetal cardiac potential signal extraction program, fetal cardiac potential signal discriminating apparatus, and pregnancy monitoring system using the same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,709,767 | Agent for prophylactic and/or therapeutic treatment of peripheral neuropathic pain caused by anticancer agent In force · From the USPTO record | In force | From the USPTO record | |
| US 9,725,519 | Antibody against transporter and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,633,358 | T-type calcium channel inhibitor In force · From the USPTO record | In force | From the USPTO record | |
| US 10,675,495 | CT Value Controller and Anticancer Agent Degradation Apparatus In force · Medium confidence | In force | Medium confidence | |
| US 12,583,938 | Protein Biomarker and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,155,804 | Composition for inducing differentiation In force · From the USPTO record | In force | From the USPTO record | |
| US 10,562,775 | Method for Producing Carbon Nanotube Sheet and Carbon Nanotube Sheet In force · High confidence | In force | High confidence |
Also on record, not counted in the 24: 4 patents in force now held by others · 30 lapsed for an unpaid fee · 3 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
13 pending · 15 abandoned · 19 no status recorded